Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cebranopadol 400 ug

Phase 3

AAdneuris Therapeutics, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Pain

NCT07845071

Clinical

Trials by Indication[1]

Pain1 trial

An Open-Label, Single-Arm, Multiple-Dose, Phase 3 Safety and Efficacy Study of Cebranopadol in Participants With Moderate to Severe Acute Pain With Surgical or Non-Surgical Origin

Recruiting·AAdneuris Therapeutics, Inc.·Phase 3·NCT07845071·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cebranopadol 400 ug. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cebranopadol 400 ug. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Adneuris Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAdneuris Therapeutics, Inc.

Related News